PURCHASE AND SALE AGREEMENT dated as of May 6, 2024 by and among AGENUS INC., AGENUS ROYALTY FUND, LLC, AGENUS HOLDINGS 2024, LLC and LIGAND PHARMACEUTICALS INCORPORATEDPurchase and Sale Agreement • August 7th, 2024 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of May 6, 2024, is by and between AGENUS, INC., a Delaware corporation (the “Company”), AGENUS ROYALTY FUND, LLC, a Delaware limited liability company (“Royalty Fund” and together with the Company, each a “Seller” and collectively, the “Sellers”), AGENUS HOLDINGS 2024, LLC, a Delaware limited liability company (“Product Sub”, and together with the Sellers, the “Seller Parties”), and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (the “Purchaser”).
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • August 7th, 2024 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), is made and entered into as of July 8, 2024, by and among LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto (the “Lenders”), and CITIBANK, N.A., as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).
Agreement on the Acquisition of Stocks in Apeiron Biologics AGStock Purchase Agreement • August 7th, 2024 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
Definitions (for convenience purposes only)Each of the following terms shall have the meaning as ascribed to it on the respective page of this Agreement (including its Preamble) containing the respective definition. Term Page Term Page
